Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States.
Imperfect balance sheet with concerning outlook.
Share Price & News
How has Organogenesis Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2PQ's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2PQ underperformed the German Biotechs industry which returned 8.9% over the past year.
Return vs Market: 2PQ underperformed the German Market which returned 0.2% over the past year.
Price Volatility Vs. Market
How volatile is Organogenesis Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Organogenesis Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 2PQ's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 2PQ's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 2PQ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2PQ is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2PQ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2PQ is overvalued based on its PB Ratio (9.5x) compared to the DE Biotechs industry average (2.9x).
How is Organogenesis Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2PQ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2PQ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2PQ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2PQ's revenue (11.6% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: 2PQ's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2PQ is forecast to be unprofitable in 3 years.
How has Organogenesis Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2PQ is currently unprofitable.
Growing Profit Margin: 2PQ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2PQ is unprofitable, and losses have increased over the past 5 years at a rate of -19.8% per year.
Accelerating Growth: Unable to compare 2PQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2PQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: 2PQ has a negative Return on Equity (-102%), as it is currently unprofitable.
How is Organogenesis Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 2PQ's short term assets ($111.4M) exceed its short term liabilities ($54.8M).
Long Term Liabilities: 2PQ's short term assets ($111.4M) do not cover its long term liabilities ($113.2M).
Debt to Equity History and Analysis
Debt Level: 2PQ's debt to equity ratio (230.9%) is considered high.
Reducing Debt: Insufficient data to determine if 2PQ's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2PQ has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 2PQ has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 38.5% each year.
What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2PQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2PQ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2PQ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2PQ's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2PQ's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gary Gillheeney (65yo)
Mr. Gary S. Gillheeney, Sr. serves as the Chief Executive Officer and President of Organogenesis Inc., since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organogenesis's ...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD1.44M) is above average for companies of similar size in the German market ($USD1.08M).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
|VP & General Counsel||3.5yrs||US$508.71k||no data|
|Chief Commercial Officer||2.83yrs||US$605.80k||0.0031% $10.8k|
|Chief Financial Officer||3.83yrs||no data||no data|
|Chief Operating Officer||2.83yrs||no data||0.11% $403.0k|
|Vice President of Human Resources||2.08yrs||no data||no data|
|Senior Vice President of Quality Systems||12.5yrs||no data||no data|
Experienced Management: 2PQ's management team is considered experienced (3.5 years average tenure).
|Director||1.58yrs||no data||7.5% $26.3m|
|Director||1.58yrs||no data||14.08% $49.4m|
|Chairman of the Board||no data||no data||8.94% $31.4m|
|Director||1.58yrs||no data||no data|
Experienced Board: 2PQ's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.
Organogenesis Holdings Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Organogenesis Holdings Inc.
- Ticker: 2PQ
- Exchange: DB
- Founded: 1985
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$394.721m
- Listing Market Cap: US$351.105m
- Shares outstanding: 106.11m
- Website: https://organogenesis.com
Number of Employees
- Organogenesis Holdings Inc.
- 85 Dan Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ORGO||NasdaqCM (Nasdaq Capital Market)||Yes||Class A Common Stock||US||USD||Jan 2019|
|2PQ||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||Jan 2019|
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company’s advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company’s pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/06 21:26|
|End of Day Share Price||2020/07/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.